Markets:

Overview

News

Currencies

International

Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.81 -0.54 (-2.13%)

Streaming Delayed Price Updated: 11:13 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

November 03, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2023 ↗

November 03, 2023

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Via Benzinga

Earnings Outlook For Arcutis Biotherapeutics ↗

November 02, 2023

Via Benzinga

Analyst Expectations for Arcutis Biotherapeutics's Future ↗

October 13, 2023

Via Benzinga

MSP Recovery And 3 Other Stocks Under $3 Insiders Are Buying ↗

October 27, 2023

The Dow Jones closed lower by over 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Arcutis to Report Third Quarter 2023 Financial Results

October 25, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Nasdaq Down Over 1%; Autoliv Raises FY23 Sales Outlook ↗

October 20, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Friday. The Dow traded down 0.61% to 33,209.97 while the NASDAQ fell 1.24% to 13,022.16. The S&P...

Via Benzinga

Topics Stocks

Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results ↗

October 20, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.31% to 33,309.28 while the NASDAQ fell 1.09% to 13,042.83. The S&P 500 also...

Via Benzinga

Topics Stocks

Where Arcutis Biotherapeutics Stands With Analysts ↗

September 25, 2023

Via Benzinga

Why Shares of Arcutis Biotherapeutics Fell This Week ↗

September 07, 2023

The company released phase 3 trial results for an atopic dermatitis cream.

Via The Motley Fool

Why Adial Pharmaceuticals Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

October 20, 2023

Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 20, 2023

Via Benzinga

New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials

October 20, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

October 20, 2023

Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

October 20, 2023

We're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching on Friday morning!

Via InvestorPlace

Arcutis Announces Pricing of $100 Million Public Offering

October 19, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 19, 2023

Via Benzinga

Arcutis Announces Proposed Public Offering

October 19, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023 ↗

October 13, 2023

Via Benzinga

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

October 13, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

October 06, 2023

Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Appoints L. Todd Edwards as Chief Commercial Officer

September 27, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗

September 26, 2023

U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis

September 25, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis ↗

September 19, 2023

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its...

Via Benzinga

Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

September 19, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

September 12, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

US Stocks Mostly Higher; RH Posts Upbeat Earnings ↗

September 08, 2023

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ...

Via Benzinga

Topics Stocks

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)

September 07, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

September 05, 2023

From Arcutis Biotherapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

All News about Arcutis Biotherapeutics, Inc. - Common stock

Starting at /week.